TD Cowen cuts Stryker stock price target on cybersecurity impact

TD Cowen cut Stryker’s price target to $355 from $387 and kept a Hold rating after a first quarter hit from a cybersecurity incident. Stryker reported Q1 2026 revenue of $6.02 billion, missing the $6.35 billion consensus by 5.36%, and EPS of $2.60 versus $2.98 expected. Management maintained full-year guidance, but analysts flagged slower recovery and reduced confidence in sustaining double-digit top-line growth.

Analysis

The market is now pricing Stryker less as a pristine compounding med-tech platform and more as a temporarily impaired operator with a recovery narrative. That distinction matters because in healthcare hardware, one or two disrupted quarters can reset sell-side confidence faster than they reset end-demand, which creates a window where valuation compresses more than fundamentals do. The key second-order effect is not just lost revenue, but deferred procedures and capital spend that can bleed into peer systems and distributors before normalizing.

The cybersecurity issue likely creates a staggered recovery: near-term, hospitals and ambulatory centers may delay replacement cycles and standardize around vendors with cleaner execution histories, even if Stryker’s product portfolio remains competitive. That can benefit rivals with less operational noise and stronger fulfillment reliability, especially in orthopedics and med-surg where purchasing committees value continuity. If the company restores service levels quickly, some of the lost volume should come back over the next 1-2 quarters; if not, the damage shifts from transient to structural as accounts re-bid share.

Consensus appears to be underestimating how much of the recent drawdown is already discounting the bad quarter, while also overestimating the ease of a clean snapback. The stock’s downside from here is likely more about multiple de-rating from weaker growth visibility than another large earnings cut; conversely, a stable operational readthrough on the next call could trigger a sharp relief rally because positioning is already cautious. The asymmetric setup is for a trading bounce, not a long-duration re-rating, unless management proves that post-incident cadence and margin recovery are intact by the next two reporting cycles.

Key Decisions for Investors

• Trade a tactical long in SYK for 4-8 weeks, sized for a 10-15% upside rebound if execution data stabilizes; use a hard stop on any evidence of delayed procedure recovery or further supply-chain friction.
• Prefer a pairs trade: long SYK / short a higher-multiple med-tech peer basket for 1-2 quarters, betting on mean reversion from incident-driven de-rating rather than sector beta; target 150-250 bps of relative outperformance.
• Buy SYK call spreads 1-2 quarters out rather than outright stock if you want event-driven upside with defined risk; the premium should cheapen as panic fades, giving a favorable convexity profile.
• If you want a lower-risk entry, wait for the next earnings/operational update and only add on confirmation that backlog fulfillment and margins are normalizing; that reduces the chance of catching a false bottom.
• Avoid expressing this as a long-term secular thesis until there are at least two clean quarters post-incident; the current setup is a recovery trade, not a confirmed growth re-acceleration story.